Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2024  >  40(4): 413-418
WANG Zongao, ZHANG Minghui, SUN Hua, OUYANG Yiran, ZHAO Lanmei, ZHANG Ting, YAO Fei, YUAN Qin, JIANG Guorong, ZHANG Lurong, LIU Min. Clinical Study on the Treatment of Advanced Liver Cancer of Qi Deficiency and Toxic Stasis Type by Jiawei Yupingfeng San[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(4): 413-418. doi: 10.14148/j.issn.1672-0482.2024.0413
Citation: WANG Zongao, ZHANG Minghui, SUN Hua, OUYANG Yiran, ZHAO Lanmei, ZHANG Ting, YAO Fei, YUAN Qin, JIANG Guorong, ZHANG Lurong, LIU Min. Clinical Study on the Treatment of Advanced Liver Cancer of Qi Deficiency and Toxic Stasis Type by Jiawei Yupingfeng San[J]. Journal of Nanjing University of traditional Chinese Medicine, 2024, 40(4): 413-418. doi: 10.14148/j.issn.1672-0482.2024.0413
shu

Clinical Study on the Treatment of Advanced Liver Cancer of Qi Deficiency and Toxic Stasis Type by Jiawei Yupingfeng San

doi: 10.14148/j.issn.1672-0482.2024.0413
  • 1.

    Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou 215009, China

  • 2.

    Department of Oncology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou 215009, China

  • 3.

    Central Laboratory of Suzhou Hospital of Traditional Chinese Medicine, Suzhou 215009, China

  • Received Date: 2023-10-20
    Available Online: 2024-04-24
    Abstract
  •   OBJECTIVE  To observe the clinical efficacy and effect on serum thymic stromal lymphopoietin (TSLP) levels of patients with advanced liver cancer of qi deficiency and toxic stasis type by Jiawei Yupingfeng San.  METHODS  Using random double blind method, 120 patients with advanced liver cancer of qi deficiency and toxic stasis type were randomly divided into 3 groups: Jiawei Yupingfeng San group, Yupingfeng San group, and placebo group, each consisting of 40 cases. All patients in the 3 groups were given conventional treatment such as radiotherapy, chemotherapy, interventional or targeted therapy; Jiawei Yupingfeng San group was given Jiawei Yupingfeng San granules, Yupingfeng San group was given Yupingfeng San granules, and placebo group was given placebo. The course of treatment was 2 months. The changes of Karnofsky functional status score (KPS score), TCM syndrome score, tumor size and serum TSLP level in the 3 groups were observed before and after treatment, and the correlation between the changes of tumor size and TSLP was analyzed.  RESULTS  After treatment, the KPS scores of Yupingfeng San group and Jiawei Yupingfeng San group were significantly increased (P < 0.05, P < 0.01), TCM syndrome score were decreased (P < 0.01), tumor growth (P < 0.05, P < 0.01) was delayed, and serum TSLP levels (P < 0.05, P < 0.01) were decreased. Furthermore, there was a slight positive correlation between changes in tumor size and changes in TSLP (P < 0.05). In terms of improving tumor size, the curative effect of Jiawei Yupingfeng San group was better than that of Yupingfeng San group (P < 0.05). During the treatment period, no obvious adverse reactions were observed in the 3 groups of patients.  CONCLUSION  Combined with conventional treatment, Jiawei Yupingfeng San can significantly delay tumor growth in patients with advanced liver cancer of qi deficiency and toxic stasis type and improve patients' TCM syndromes and their quality of survival. The therapeutic mechanism is related to reducing the expression of serum TSLP and improving the immune status of patients, thereby delaying the growth of tumors.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. doi: 10.1016/S0140-6736(22)01200-4
    [2]
    ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
    [3]
    陈楚钦, 施练迅, 汤子明, 等. 索拉菲尼对不同肝功能 Child-Pugh 分级晚期肝癌患者的疗效和安全性比较[J]. 广东医学, 2017, 38(18): 2865-2867. doi: 10.3969/j.issn.1001-9448.2017.18.035

    CHEN C Q, SHI L X, TANG Z M, et al. Comparison of efficacy and safety of sorafenib in patients with advanced liver cancer with different Child-Pugh grades of liver function[J]. Guangdong Med J, 2017, 38(18): 2865-2867. doi: 10.3969/j.issn.1001-9448.2017.18.035
    [4]
    HE W, LIAO L E, HU D D, et al. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: A preliminary study[J]. Ann Transl Med, 2020, 8(16): 1000. doi: 10.21037/atm-20-5298
    [5]
    LIU X L, LI M G, WANG X H, et al. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma[J]. Phytomedicine, 2019, 62: 152930.
    [6]
    刘展华, 庄振杰, 黄慈辉, 等. 肝癌炎性微环境与中医药干预疗法概述[J]. 广州中医药大学学报, 2018, 35(5): 937-942. https://www.cnki.com.cn/Article/CJFDTOTAL-REST201805038.htm

    LIU Z H, ZHUANG Z J, HUANG C H, et al. Overview of inflammatory micro-environment of hepatocellular carcinoma and related Chinese medicine intervention therapies[J]. J Guangzhou Univ Tradit Chin Med, 2018, 35(5): 937-942. https://www.cnki.com.cn/Article/CJFDTOTAL-REST201805038.htm
    [7]
    VARRICCHI G, PECORARO A, MARONE G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer[J]. Front Immunol, 2018, 9: 1595. doi: 10.3389/fimmu.2018.01595
    [8]
    曹志新, 陈孝平, 吴在德. 肝癌合并肝硬化患者脾脏Th1/Th2细胞因子免疫状态的研究[J]. 中华实验外科杂志, 2001, 18(6): 518-519. doi: 10.3760/j.issn:1001-9030.2001.06.016

    CAO Z X, CHEN X P, WU Z D. A study on the spleen Th1/Th2 cytokines immunological condition in the patients with primary hepatocellular carcinoma combined with liver cirrhosis[J]. Chin J Exp Surg, 2001, 18(6): 518-519. doi: 10.3760/j.issn:1001-9030.2001.06.016
    [9]
    程海波, 吴勉华. 周仲瑛教授"癌毒" 学术思想探析[J]. 中华中医药杂志, 2010, 25(6): 866-869. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201006022.htm

    CHENG H B, WU M H. Discussion on academic thought of Professor ZHOU Zhong-ying about cancerous toxin[J]. China J Tradit Chin Med Pharm, 2010, 25(6): 866-869. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201006022.htm
    [10]
    赵素霞, 刘会丽, 樊峥, 等. 玉屏风散辅助治疗原发性肝癌的疗效及对抗肿瘤免疫的影响[J]. 肿瘤药学, 2017, 7(6): 713-717. doi: 10.3969/j.issn.2095-1264.2017.06.15

    ZHAO S X, LIU H L, FAN Z, et al. Influence of Yupingfeng Powder adjuvant therapy on treatment effect and anti-tumor immunity of patients with primary liver cancer[J]. Anti Tumor Pharm, 2017, 7(6): 713-717. doi: 10.3969/j.issn.2095-1264.2017.06.15
    [11]
    袁琴, 姚霏, 张露蓉. 玉屏风散通过胸腺基质淋巴细胞生成素改变Th1/Th2的平衡发挥抗肝癌效应的研究[J]. 南通大学学报(医学版), 2016, 36(6): 509-513. https://www.cnki.com.cn/Article/CJFDTOTAL-NTYX201606001.htm

    YUAN Q, YAO F, ZHANG L R. Research on inhibition effects of Yupingfeng Powder through TSLP change the balance of Th1/Th2 in hepatocellular carcinoma[J]. J Nantong Univ Med Sci, 2016, 36(6): 509-513. https://www.cnki.com.cn/Article/CJFDTOTAL-NTYX201606001.htm
    [12]
    刘敏, 王明武. 解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究[J]. 南京中医药大学学报, 2016, 32(2): 111-113. http://xb.njucm.edu.cn/article/id/zr20160204

    LIU M, WANG M W. Clinical research on the inhibition of recurrence and metastasis of triple negative breast cancer with the method of detoxification and blood stasis dissipating[J]. J Nanjing Univ Tradit Chin Med, 2016, 32(2): 111-113. http://xb.njucm.edu.cn/article/id/zr20160204
    [13]
    张琳, 高勇. 复方红豆杉胶囊对Walker-256移植性肝癌大鼠HIF-1α、VEGF及PCNA表达的影响[J]. 陕西中医, 2019, 40(2): 148-151, 155. doi: 10.3969/j.issn.1000-7369.2019.02.003

    ZHANG L, GAO Y. The effects of Fufang Hongdoushan capsule in the expression of HIF-1α, VEGF and PCNA in Walker-256 transplanted liver cancer rats[J]. Shaanxi J Tradit Chin Med, 2019, 40(2): 148-151, 155. doi: 10.3969/j.issn.1000-7369.2019.02.003
    [14]
    刘同祥, 张艳平, 徐羽, 等. 紫杉醇联合三尖杉宁碱诱导人肝癌HepG2细胞凋亡[J]. 中国实验方剂学杂志, 2010, 16(9): 115-118, 122. doi: 10.3969/j.issn.1005-9903.2010.09.035

    LIU T X, ZHANG Y P, XU Y, et al. Effect of taxol combining with cephalomannine on apoptosis of liver cancer cell HepG2[J]. Chin J Exp Tradit Med Formulae, 2010, 16(9): 115-118, 122. doi: 10.3969/j.issn.1005-9903.2010.09.035
    [15]
    王海永, 张晨月, 李佳, 等. 蟾毒灵抑制肝癌干细胞lncRNAs分子筛选研究[J]. 中国中医药信息杂志, 2021, 28(12): 41-44. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202112008.htm

    WANG H Y, ZHANG C Y, LI J, et al. Study on screening of lncRNAs involved in the inhibitory effect of bufalin on hepatocellular carcinoma stem cells[J]. Chin J Inf Tradit Chin Med, 2021, 28(12): 41-44. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202112008.htm
    [16]
    袁贤达, 王骏, 金明吉, 等. 华蟾素油剂对肝癌细胞的体内外抑制活性及肿瘤微环境中对免疫细胞的影响[J]. 世界中西医结合杂志, 2019, 14(12): 1629-1637. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX201912002.htm

    YUAN X D, WANG J, JIN M J, et al. Inhibitory activity of Huachansu corn oil solvent on liver cancer cells in vitro and in vivo and effects on immune cells in tumor microenvironment[J]. World J Integr Tradit West Med, 2019, 14(12): 1629-1637. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX201912002.htm
    [17]
    周星言, 戴国瑶. 雷公藤甲素通过调节沉默信息调节因子1/p53途径抑制肝癌HepG2细胞的增殖和迁移[J]. 胃肠病学和肝病学杂志, 2022, 31(10): 1178-1182. doi: 10.3969/j.issn.1006-5709.2022.10.020

    ZHOU X Y, DAI G Y. Triptolide inhibits proliferation and migration of liver cancer HepG2 cells by regulating the silent information regulator 1/p53 pathway[J]. Chin J Gastroenterol Hepatol, 2022, 31(10): 1178-1182. doi: 10.3969/j.issn.1006-5709.2022.10.020
    [18]
    顾军花, 刘嘉湘. 刘嘉湘教授"扶正治癌" 理论核心及运用方法[J]. 中国中西医结合杂志, 2017, 37(4): 495-499. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201704028.htm

    GU J H, LIU J X. Core of professor Liu Jiaxiang's theory of "strengthening the body resistance and treating cancer" and its application method[J]. Chin J Integr Tradit West Med, 2017, 37(4): 495-499. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201704028.htm
    [19]
    《原发性肝癌诊疗规范(2017年版)》编写专家委员会. 原发性肝癌诊疗规范(2017年版)[J]. 消化肿瘤杂志(电子版), 2017, 9(4): 213-228. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201907004.htm

    Expert Committee for the Compilation of Diagnosis and Treatment Standards for Primary Liver Cancer (2017 Edition). Diagnosis and treatment standards for primary liver cancer (2017 edition)[J]. J Dig Oncol Electron Version, 2017, 9(4): 213-228. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ201907004.htm
    [20]
    中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002.

    Guiding principles for clinical research of new Chinese medicine: Trial implementation[M]. Beijing: China Medical Science and Technology Press, 2002.
    [21]
    中国癌症基金会. 基层医生肿瘤诊治手册[M]. 北京: 北京大学医学出版社, 2008.

    China Cancer Foundation. Handbook for cancer diagnosis and treatment for primary doctors[M]. Beijing: Peking University Medical Press, 2008.
    [22]
    EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
    [23]
    PROTTI M P, DE MONTE L. Thymic stromal lymphopoietin and cancer: Th2-dependent and-independent mechanisms[J]. Front Immunol, 2020, 11: 2088. doi: 10.3389/fimmu.2020.02088
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(9)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (63) PDF downloads(12) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return